The Universities of Birmingham and Oxford are to take part in one of five new NHS Blood and Transplant (NHSBT) research units. Published 17 May 20223 min read The 20m programme, co-funded by the National Institute for Health and Care Research (NIHR) and NHSBT - are aimed at providing new technologies, techniques or insights that will benefit donation, transfusion, and transplantation. The NIHR BTRUs are partnerships between universities and NHSBT.
By Deborah Borfitz May 19, 2022 | The fast-growing Consortium for Outcome Measures and Biomarkers for Neurodevelopmental Disorders (COMBINEDBrain) represents patient advocacy organizations for individuals with rare, neurodevelopmental diseases who are disadvantaged by the small number of affected individuals and scientific brainpower to lead the way. Since its launch two years ago, right before the pandemic struck, COMBINEDBrain has been engaged in a multitude of projectsranging from assisting with disorder identification and the development of disease-specific basic research models and experimental design to adapting outcome measures, identifying novel biomarkers, and interacting with the U.S. Food and Drug Administration (FDA), according to Terry Jo Bichell, MPH, Ph.D., the organizations founder and director.
Photo: POC Manufacturing/Courtesy of Orgenesis Orgenesis is developing a point-of-care manufacturing platform for cell and gene and other advanced therapies to make them more widely available and significantly more affordable. The platform is based on regional point-of-care (POCenters) and Orgenesis mobile production units or labs (OMPULs).
Evelyn Yim and Aiping Yu, both chemical engineering professors, have been designated University of Waterloo Research Chairs along with seven other professors across the campus. Yim, who joined Waterloo Engineering in 2016, is an expert in nanofabrication technologies and is one of the leading researchers studying the use of synthetic materials for altering stem cell behavior and differentiation of stem cell culture
RYE BROOK, N.Y., May 19, 2022 /PRNewswire/ -- Each year, the global leader in the fight against blood cancer, The Leukemia & Lymphoma Society (LLS),looks for opportunities to reach new heights to move towards its ultimate goal a world without blood cancer. As part of its iconic Team In Training fundraising portfolio, LLS is encouraging communities and individuals nationwide to join its virtual fitness challenge, Resilience Challenge, which is designed to help individuals of all levels reimagine their health goals all while fighting blood cancer. Left to right: Team In Trainings Resilience Challenge Team SoulFamily teammates, blood cancer survivor, Tracy Nathan and Maria Martell at a local fundraiser in California
We live in a time of spectacular scientific discoveries. Last week, we saw the first image ever recorded of the giant black hole at the center of the Milky Way. The James Webb Space Telescope is ready to start sending images of the earliest stars, helping us tell the story of our cosmic origins
Athersys (NASDAQ:ATHX Get Rating) was upgraded by Zacks Investment Research from a sell rating to a hold rating in a report released on Wednesday, Zacks.com reports. According to Zacks, Athersys, Inc., a late stage biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused primarily on treating critical care indications neurological conditions, cardiovascular diseases, inflammatory and immune disorders, pulmonary and other conditions
The Maryland Stem Cell Research Commission announced Monday it will grant$7,067,409in award funding to innovative research that will strengthen and advance stem cell treatments and technologies inMaryland.
New York, May 17, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Cell & Gene Therapy Manufacturing Services Market Research Report by Type, Indication, Application, End-User, State - United States Forecast to 2027 - Cumulative Impact of COVID-19" - https://www.reportlinker.com/p06276880/?utm_source=GNW The United States Cell & Gene Therapy Manufacturing Services Market size was estimated at USD 2,730.31 million in 2021 and expected to reach USD 3,066.89 million in 2022, and is projected to grow at a CAGR 14.39% to reach USD 6,118.58 million by 2027.
Dr. Thomas Hornyak, associate chief of staff of Research & Development at the VA Maryland Health Care System, and Associate Professor and Chair of the Department of Dermatology at the University of Maryland School of Medicine, has been selected to receive the American Skin Association (ASA)'s 2022 Research Achievement Award in Vitiligo and Pigment Cell Disorders.
Recent Comments